Cargando…
Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study
The prognosis of leptomeningeal metastasis (LM) from solid tumors is extremely poor, especially for patients with adverse prognostic factors. In this phase II clinical trial, we evaluated the efficacy and safety of intrathecal chemotherapy (IC) combined with concomitant involved‐field radiotherapy (...
Autores principales: | Pan, Zhenyu, Yang, Guozi, He, Hua, Zhao, Gang, Yuan, Tingting, Li, Yu, Shi, Weiyan, Gao, Pengxiang, Dong, Lihua, Li, Yunqian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096248/ https://www.ncbi.nlm.nih.gov/pubmed/27243238 http://dx.doi.org/10.1002/ijc.30214 |
Ejemplares similares
-
Leptomeningeal metastasis from solid tumors: clinical features and its diagnostic implication
por: Pan, Zhenyu, et al.
Publicado: (2018) -
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
por: Ratosa, Ivica, et al.
Publicado: (2022) -
Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study
por: Pan, Zhenyu, et al.
Publicado: (2020) -
A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer
por: Pan, Zhenyu, et al.
Publicado: (2019) -
A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)